Ceftolozane-Tazobactam + Meropenem
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bacteremia Caused by Gram-Negative Bacteria
Conditions
Bacteremia Caused by Gram-Negative Bacteria
Trial Timeline
Jan 1, 2022 → Dec 1, 2024
NCT ID
NCT04238390About Ceftolozane-Tazobactam + Meropenem
Ceftolozane-Tazobactam + Meropenem is a phase 3 stage product being developed by Merck for Bacteremia Caused by Gram-Negative Bacteria. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04238390. Target conditions include Bacteremia Caused by Gram-Negative Bacteria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06342115 | Approved | Recruiting |
| NCT04238390 | Phase 3 | Withdrawn |
Competing Products
9 competing products in Bacteremia Caused by Gram-Negative Bacteria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin + Comparator | Merck | Approved | 85 |
| Daptomycin for Injection | Merck | Phase 2 | 52 |
| Vancomycin + Daptomycin | Merck | Approved | 85 |
| Cefazolin IV + Linezolid IV + Vancomycin (IV) | Pfizer | Phase 3 | 76 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| ceftobiprole medocaril | Basilea Pharmaceutica | Phase 2 | 47 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| AP-SA02 | Armata Pharmaceuticals | Phase 1/2 | 33 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |